VenomAid Diagnostics

Executive Summary

VenomAid Diagnostics is a Danish medtech company founded in 2019 with a mission to reduce the global burden of snakebite envenoming through affordable, rapid point-of-care diagnostic tests. Snakebites cause over 100,000 deaths annually, primarily in low-resource settings, but current diagnostics are slow and poorly suited for field use. VenomAid's platform aims to identify venom type within minutes using a disposable test strip and a handheld reader, enabling clinicians to administer the correct antivenom quickly. The company has made progress in assay development and initial clinical validation, positioning itself to address a critical unmet need in tropical medicine. With a strong focus on low-cost manufacturing and ease of use, VenomAid could become a vital tool for healthcare workers in endemic regions.

Upcoming Catalysts (preview)

• Q1 2027Completion of clinical validation study in Sub-Saharan Africa70% success
• Q3 2026Series A funding round to support regulatory approval and manufacturing scale-up80% success
• Q4 2026WHO prequalification submission for the diagnostic test50% success